Suspected non-AD pathology in mild cognitive impairment

Neurobiology of Aging

Volumn 36, Issue 12, 2015, Pages 3152-3162

  Wisse, Laura E M ^a   Butala, Nirali ^a   Das, Sandhitsu R ^a   Davatzikos, Christos ^a   Dickerson, Bradford C ^b   Vaishnavi, Sanjeev N ^a   Yushkevich, Paul A ^a   Wolk, David A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyloidosis; Cerebrovascular disease; Cognition; Mild cognitive impairment; Primary age related tauopathy; Suspected non AD pathology

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BRAIN SIZE; CEREBROVASCULAR DISEASE; COGNITION; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; WHITE MATTER; COGNITIVE DEFECT; METABOLISM; MIDDLE AGED; PATHOLOGY; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITION; COGNITIVE DYSFUNCTION; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MEMORY; MIDDLE AGED; NERVE DEGENERATION; NEUROIMAGING; PEPTIDE FRAGMENTS;

EID: 84946562079     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.08.029     Document Type: Article

References (52)

1. Aisen P.S., Petersen R.C., Donohue M.C., Gamst A., Raman R., Thomas R.G., Walter S., Trojanowski J.Q., Shaw L.M., Beckett L.A., Jack C.R., Jagust W., Toga A.W., Saykin A.J., Morris J.C., Green R.C., Weiner M.W. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010, 6:239-246. Alzheimer's Disease Neuroimaging Initiative.
2. Ariza M., Kolb H.C., Moechars D., Rombouts F.J., Andres J.I. Tau PET imaging: past, present and future. J. Med. Chem. 2015, 58:4365-4382.
3. Au R., Massaro J.M., Wolf P.A., Young M.E., Beiser A., Seshadri S., D'Agostino R.B., DeCarli C. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch. Neurol. 2006, 63:246-250.
4. Avants B.B., Epstein C.L., Grossman M., Gee J.C. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med. Image Anal. 2008, 12:26-41.
5. Avants B.B., Tustison N.J., Wu J., Cook P.A., Gee J.C. An open source multivariate framework for n-tissue segmentation with evaluation on public data. Neuroinformatics 2011, 9:381-400.
6. Beauchet O., Celle S., Roche F., Bartha R., Montero-Odasso M., Allali G., Annweiler C. Blood pressure levels and brain volume reduction: a systematic review and meta-analysis. J. Hypertens 2013, 31:1502-1516.
7. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
8. Butters N., Granholm E., Salmon D.P., Grant I., Wolfe J. Episodic and semantic memory: a comparison of amnesic and demented patients. J. Clin. Exp. Neuropsychol. 1987, 9:479-497.
9. Carmichael O., Schwarz C., Drucker D., Fletcher E., Harvey D., Beckett L., Jack C.R., Weiner M., DeCarli C. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch. Neurol. 2010, 67:1370-1378. Alzheimer's Disease Neuroimaging Initiative.
10. Caroli A., Prestia A., Galluzzi S., Ferrari C., van der Flier W.M., Ossenkoppele R., Van Berckel B., Barkhof F., Teunissen C., Wall A.E., Carter S.F., Scholl M., Choo I.H., Grimmer T., Redolfi A., Nordberg A., Scheltens P., Drzezga A., Frisoni G.B. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 2015, 84:508-515. For the Alzheimer's Disease Neuroimaging Initiative.
11. Chowdhury M.H., Nagai A., Bokura H., Nakamura E., Kobayashi S., Yamaguchi S. Age-related changes in white matter lesions, hippocampal atrophy, and cerebral microbleeds in healthy subjects without major cerebrovascular risk factors. J.Stroke Cerebrovasc. Dis. 2011, 20:302-309.
12. Crary J.F., Trojanowski J.Q., Schneider J.A., Abisambra J.F., Abner E.L., Alafuzoff I., Arnold S.E., Attems J., Beach T.G., Bigio E.H., Cairns N.J., Dickson D.W., Gearing M., Grinberg L.T., Hof P.R., Hyman B.T., Jellinger K., Jicha G.A., Kovacs G.G., Knopman D.S., Kofler J., Kukull W.A., Mackenzie I.R., Masliah E., McKee A., Montine T.J., Murray M.E., Neltner J.H., Santa-Maria I., Seeley W.W., Serrano-Pozo A., Shelanski M.L., Stein T., Takao M., Thal D.R., Toledo J.B., Troncoso J.C., Vonsattel J.P., White C.L., Wisniewski T., Woltjer R.L., Yamada M., Nelson P.T. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014, 128:755-766.
13. Das S.R., Avants B.B., Grossman M., Gee J.C. Registration based cortical thickness measurement. Neuroimage 2009, 45:867-879.
14. Das S.R., Mancuso L., Olson I.R., Arnold S.E., Wolk D.A. Short-Term memory depends on dissociable medial temporal lobe regions in amnestic mild cognitive impairment. Cereb. Cortexa 2015, Epub ahead of print.
15. Das S.R., Pluta J., Mancuso L., Kliot D., Yushkevich P.A., Wolk D.A. Anterior and posterior MTL networks in aging and MCI. Neurobiol. Aging 2015, 36(Suppl 1):S141-S150.e1.
16. Davatzikos, C., Erus, G., Da, X., Doshi, J., Hierarchical Parcellation of MRI Using Multi-atlas Labeling Methods. Available at: , 2014. http://adni.bitbucket.org/upenn_roi_mars.html.
17. den Heijer T., Launer L.J., Prins N.D., van Dijk E.J., Vermeer S.E., Hofman A., Koudstaal P.J., Breteler M.M. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005, 64:263-267.
18. Duara R., Loewenstein D.A., Shen Q., Barker W., Potter E., Varon D., Heurlin K., Vandenberghe R., Buckley C. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2013, 9:295-301.
19. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
20. Grober E., Sliwinski M. Development and validation of a model for estimating premorbid verbal intelligence in the elderly. J. Clin. Exp. Neuropsychol. 1991, 13:933-949.
21. Gross A.L., Manly J.J., Pa J., Johnson J.K., Park L.Q., Mitchell M.B., Melrose R.J., Inouye S.K., McLaren D.G. Cortical signatures of cognition and their relationship to Alzheimer's disease. Brain Imaging Behav. 2012, 6:584-598. Alzheimer's Disease Neuroimaging Initiative.
22. Jack C.R. PART and SNAP. Acta Neuropathol. 2014, 128:773-776.
23. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
24. Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Rocca W.A., Boeve B.F., Petersen R.C. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 2012, 71:765-775.
25. Jack C.R., Wiste H.J., Weigand S.D., Knopman D.S., Lowe V., Vemuri P., Mielke M.M., Jones D.T., Senjem M.L., Gunter J.L., Gregg B.E., Pankratz V.S., Petersen R.C. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013, 81:1732-1740.
26. Kaplan E., Goodglass H., Weintraub S. The Boston Naming Test 1983, Lea and Febiger, Philadelphia.
27. Knopman D.S., Jack C.R., Wiste H.J., Weigand S.D., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Boeve B.F., Petersen R.C. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
28. Knopman D.S., Jack C.R., Wiste H.J., Weigand S.D., Vemuri P., Lowe V.J., Kantarci K., Gunter J.L., Senjem M.L., Mielke M.M., Roberts R.O., Boeve B.F., Petersen R.C. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann. Neurol. 2013, 73:472-480.
29. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., Weiner M.W., Jagust W.J. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012, 72:578-586. Alzheimer's Disease Neuroimaging Initiative.
30. Mormino E.C., Betensky R.A., Hedden T., Schultz A.P., Amariglio R.E., Rentz D.M., Johnson K.A., Sperling R.A. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014, 71:1379-1385.
31. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
32. Nelson H.E., O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex 1978, 14:234-244.
33. Nichols T.E., Holmes A.P. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum. Brain Mapp. 2002, 15:1-25.
34. Petersen R.C., Aisen P., Boeve B.F., Geda Y.E., Ivnik R.J., Knopman D.S., Mielke M., Pankratz V.S., Roberts R., Rocca W.A., Weigand S., Weiner M., Wiste H., Jack C.R. Mild cognitive impairment due to Alzheimer disease in the community. Ann. Neurol. 2013, 74:199-208.
35. Petersen R.C., Parisi J.E., Dickson D.W., Johnson K.A., Knopman D.S., Boeve B.F., Jicha G.A., Ivnik R.J., Smith G.E., Tangalos E.G., Braak H., Kokmen E. Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. 2006, 63:665-672.
36. Prestia A., Caroli A., van der Flier W.M., Ossenkoppele R., Van Berckel B., Barkhof F., Teunissen C.E., Wall A.E., Carter S.F., Scholl M., Choo I.H., Nordberg A., Scheltens P., Frisoni G.B. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013, 80:1048-1056.
37. Prins N.D., van Dijk E.J., den Heijer T., Vermeer S.E., Jolles J., Koudstaal P.J., Hofman A., Breteler M.M. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005, 128:2034-2041.
38. Reitan, R.M., 1958. Validity of the trail making test as an indicator of organic brain damage. 8, 271-276.
39. Rey A. L'examen clinique en psychologie 1964, Presses Universitaires de France, Paris.
40. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 1984, 141:1356-1364.
41. Saykin A.J., Shen L., Foroud T.M., Potkin S.G., Swaminathan S., Kim S., Risacher S.L., Nho K., Huentelman M.J., Craig D.W., Thompson P.M., Stein J.L., Moore J.H., Farrer L.A., Green R.C., Bertram L., Jack C.R., Weiner M.W. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 2010, 6:265-273. Alzheimer's Disease Neuroimaging Initiative.
42. Schwarz C., Fletcher E., DeCarli C., Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf. Process. Med. Imaging 2009, 21:239-251.
43. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413. Alzheimer's Disease Neuroimaging Initiative.
44. Sheikh J.I., Yesavage J.A. Geriatric Depression Scale (GDS): recent evidence and development of a shorter versioin. Clinical Gerontology: A Guide to Assessment and Intervention 1986, 165-173. The Haworth Press, Inc., New York. T.L. Brink (Ed.).
45. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H., Bannister P.R., De Luca M., Drobnjak I., Flitney D.E., Niazy R.K., Saunders J., Vickers J., Zhang Y., De Stefano N., Brady J.M., Matthews P.M. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23(Suppl 1):S208-S219.
46. Smith S.M., Nichols T.E. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009, 44:83-98.
47. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
48. Tuladhar A.M., Reid A.T., Shumskaya E., de Laat K.F., van Norden A.G., van Dijk E.J., Norris D.G., de Leeuw F.E. Relationship between white matter hyperintensities, cortical thickness, and cognition. Stroke 2015, 46:425-432.
49. Tustison N.J., Cook P.A., Klein A., Song G., Das S.R., Duda J.T., Kandel B.M., van Strien N., Stone J.R., Gee J.C., Avants B.B. Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements. Neuroimage 2014, 99:166-179.
50. Vemuri P., Simon G., Kantarci K., Whitwell J.L., Senjem M.L., Przybelski S.A., Gunter J.L., Josephs K.A., Knopman D.S., Boeve B.F., Ferman T.J., Dickson D.W., Parisi J.E., Petersen R.C., Jack C.R. Antemortem differential diagnosis of dementia pathology using structural MRI: differential-STAND. Neuroimage 2011, 55:522-531.
51. Vos S.J., Xiong C., Visser P.J., Jasielec M.S., Hassenstab J., Grant E.A., Cairns N.J., Morris J.C., Holtzman D.M., Fagan A.M. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013, 12:957-965.
52. Wirth M., Villeneuve S., Haase C.M., Madison C.M., Oh H., Landau S.M., Rabinovici G.D., Jagust W.J. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013, 70:1512-1519.